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Introduction:	   Uveitis	   is	   a	   well-­‐known	   extra-­‐rheumatological	   manifestation	   of	   juvenile	   idiopathic	  
arthritis	   (JIA).	   Tumour	   necrosis	   factor	   (TNF)	   has	   been	   used	   to	   treat	   uveitis	   associated	   with	  
inflammatory	  diseases.	  A	  new-­‐onset	  uveitis	  under	  anti-­‐TNF	  therapy	  is	  uncommon.	  
	  
Case	   presentation:	   A	   12-­‐year-­‐old	   male,	   affected	   since	   the	   age	   of	   6	   years,	   by	   a	   severe	   form	   of	  
polyarticular	  JIA.	  When	  etanercept	  was	  started,	  he	  presented	  panuveitis	  bilaterally,	  so	  we	  switched	  
to	  infliximab	  with	  good	  response.	   	  
	  
Conclusions:	   The	   TNF-­‐soluble	   receptor	   could	   be	   considered	   as	   a	   possible	   promoter	   in	   inducing	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Introduction	   	  
Juvenile	   idiopathic	   arthritis	   (JIA)	   is	   the	  most	   common	   rheumatic	   disease	   in	   children.	   Uveitis	   is	   a	  
well-­‐known	   extra-­‐rheumatological	   manifestation	   of	   JIA	   which	   may	   lead	   to	   severe	   functional	  
impairment.	   Tumour	   necrosis	   factor	   (TNF)-­‐alpha	   blocking	   agents	   are	   increasingly	   used	   to	   treat	  
children	  with	  JIA	  refractory	  to	  conventional	  therapy.	  Most	  reports	  have	  demonstrated	  resolution	  of	  
refractory	  uveitis	  under	  anti-­‐TNFα.	  However,	   cases	  of	  new-­‐onset	  uveitis	  under	  anti-­‐TNFα	   therapy	  
are	  rarely	  reported.	   	  
We	   report	   herein	   a	   new	   case	   of	   paradoxical	   new	   onset	   of	   uveitis	   occurring	   under	   etanercept	  
treatment	  in	  a	  patient	  with	  JIA.	   	  
	  
Case	  Report	  
A	  6-­‐year-­‐old	  male	  child	  with	  no	  significant	  past	  medical	  or	  family	  history	  presented	  with	  progressive	  
polyarthralgia	  and	  morning	  stiffness.	  Physical	  examination	  revealed	  bilateral	  arthritis	  of	  the	  wrists,	  
proximal	   interphalangeal	   joint,	   knees	   and	   ankles.	   Laboratory	   findings	   showed	   an	   increase	   in	  
C-­‐reactive	  protein	  (CRP)	  level	  and	  erythrocyte	  sedimentation	  rate	  (ESR).	  The	  rheumatoid	  factor	  and	  
antinuclear	  antibodies	  (ANA)	  titres	  were	  negative.	  Knee	  joint	  X-­‐ray	  showed	  soft	  tissue	  swelling	  and	  
wrist	  joint	  X-­‐ray	  showed	  osteoporotic	  changes	  in	  the	  epiphysis	  of	  the	  lower	  end	  of	  radius	  and	  ulna.	  
Ophthalmological	  exam	  was	  normal.	  A	  diagnosis	  of	  seronegative	  polyarticular	  JIA	  was	  established.	  
Methotrexate	   treatment	   (10	   mg/m2	   weekly)	   was	   conducted,	   leading	   to	   complete	   resolution	   of	  
articular	  manifestations.	  After	  6	  years	  of	   clinical	   remission	  under	  methotrexate,	  a	   severe	  arthritis	  
flare	   occurred.	   His	   joint	   disease	   was	   active	   as	   shown	   by	   DAS	   28	   at	   5.1,	   while	   ophthalmologic	  
examination	   with	   slit	   lamp	   did	   not	   show	   any	   signs	   of	   uveitis.	   Laboratory	   findings	   again	   showed	  
increased	   ESR	   and	   CRP	   levels.	   Etanercept	   was	   administered	   subcutaneously	   at	   0.4mg/kg	   twice	  
weekly	  and	  methotrexate	  was	  continued.	  Two	  weeks	  after	  the	  first	  injection,	  and	  for	  the	  first	  time	  
during	   his	   longstanding	   disease,	   he	   presented	   with	   painful	   red	   eyes	   and	   photophobia.	  
Ophthalmologic	   examination	   revealed	   anterior	   and	   posterior	   chamber	   inflammation	   of	   the	   two	  
eyes.	   He	   was	   treated	   with	   oral	   steroids	   and	   beta-­‐blocker	   ophthalmic	   drops.	   Etanercept	   was	  
suspended	  and	  infliximab	  was	  started,	  with	  no	  side	  effects.	  There	  was	  a	  rapid	  decrease	  in	  his	  ocular	  
inflammation	   and	   improvement	   in	   his	   eye	   disease.	   After	   20	   months,	   arthritis	   was	   stable	   and	  
complete	  remission	  of	  uveitis	  was	  obtained.	   	   	  
	  
Discussion	  
JIA	  is	  the	  most	  common	  cause	  of	  chronic	  anterior	  uveitis	  in	  childhood.	  Uveitis	  is	  strongly	  associated	  
with	  the	  oligoarticular	  and	  seronegative	  polyarticular	  subgroups	  or	  the	  presence	  of	  ANA.	  Uveitis	  in	  
JIA	   can	   worsen	   over	   time,	   with	   many	   sight-­‐threatening	   complications,	   such	   as	   cataracts,	  
keratopathies,	  synechiae	  and	  glaucoma.	  Posterior	  segment	   involvement	   in	  JIA	   is	  rare.	  This	  patient	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Studies	  have	  shown	  that	  etanercept	  is	  associated	  with	  a	  risk	  of	  new-­‐onset	  uveitis	  and	  uveitis	  flares	  
in	   JIA	   patients.	   We	   are	   aware	   of	   only	   13	   cases	   of	   new-­‐onset	   uveitis	   in	   JIA	   under	   TNF	   blockers,	  




All	  these	  JIA	  cases	  were	  treated	  with	  etanercept.	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is	  unknown.	  In	  fact,	  the	  link	  between	  etanercept	  and	  uveitis	   is	  quite	  complex	  and	  there	  are	  many	  
controversies.	   Some	   observations	   suggest	   that	   etanercept	   is	   not	   involved	   in	   generating	   uveitis.	  
Schmeling	  and	  Horneff	   [6]	   reported	  a	   cohort	  of	  229	   JIA	  patients	   treated	  with	  etanercept.	  Of	   this	  
cohort,	   only	   two	   patients	   developed	   new-­‐onset	   uveitis	   after	   initiation	   of	   etanercept,	   whereas	  
several	  others	  experienced	  a	   flare	  of	   their	  previously	  diagnosed	  uveitis.	  Despite	   this,	   the	  authors	  
concluded	   that	   etanercept	   treatment	   did	   not	   influence	   the	   incidence	   and	   course	   of	   JIA-­‐related	  
uveitis.	   	  
Furthermore,	   some	  clinicians	  believe	   that	  etanercept	  may	   trigger	  uveitis	   in	   a	   susceptible	  patient,	  
despite	  its	  efficacy	  in	  treating	  joint	  diseases.	  Scrivo	  reported	  a	  cohort	  of	  350	  patients	  treated	  with	  
etanercept,	   in	   whom	   new-­‐onset	   anterior	   uveitis	   occurred	   in	   four,	   including	   one	  with	   JIA[7].	   The	  
authors	  suggested	  that	  monoclonal	  anti-­‐TNF	  treatment,	  especially	  adalimumab[8],	  is	  preferable	  to	  
the	  soluble	  TNF	  receptor	  agent	  in	  patients	  experiencing	  recurrent	  uveitis	  flares.	  Uveitis	  onset	  may	  
be	  considered	  as	  a	  paradoxical	  effect	  of	  anti-­‐TNF	  therapy,	  so	  called	  because	  it	  appeared	  after	  the	  
initiation	  of	  the	  anti-­‐TNF	  drugs	  that	  are	  normally	  used	  to	  treat	  it.	  In	  the	  majority	  of	  the	  cases	  in	  the	  
literature,	   uveitis	   appeared	   at	   a	   time	   during	   which	   rheumatic	   disease	   manifestations	   were	   fully	  
controlled,	  but	  in	  our	  patient	  the	  uveitis	  occurred	  during	  a	  JIA	  flare.	  The	  uveitis	  onset	  occurred	  after	  
an	  average	  duration	  of	  exposure	  to	  etanercept	  of	  12.5	  months	  (US	  registry)	  [9].	  Our	  case	  is	  original	  
since	  uveitis	  appears	  after	  the	  first	  injection	  and	  it	  was	  a	  panuveitis,	  suggesting	  that	  etanercept	  had	  
a	  role	  in	  the	  onset	  of	  uveitis.	   	  
Treatment	  of	  new-­‐onset	  uveitis	  under	  anti-­‐TNF	  was	  local	  in	  most	  of	  the	  cases,	  with	  healing	  of	  the	  
episode	  within	  2	  months.	  Discontinuation	  of	  anti-­‐TNF	  could	  be	  necessary	  in	  some	  cases.	  In	  the	  US	  
registry[9],	  four	  cases	  of	  uveitis	  under	  etanercept	  resolved	  after	  discontinuing	  the	  medication,	  with	  
a	  recurrence	  of	  uveitis	  on	  rechallenge	  in	  two	  of	  these	  patients.	  In	  our	  case,	  uveitis	  resolved	  under	  
oral	  corticosteroids	  and	  when	  etanercept	  was	  switched	  to	  infliximab.	  Adalimumab	  is	  considered	  the	  
most	  effective	  anti-­‐TNF	  in	  the	  treatment	  of	  uveitis	  associated	  with	  oligo-­‐	  and	  polyarticular	  JIAs,	  but	  




• Paradoxical	  uveitis	  can	  occur	  early	  after	  the	  initiation	  of	  etanercept.	   	  
• Consider	   bilateral	   panuveitis,	   which	   is,	   to	   our	   knowledge,	   the	   first	   case	   described	   as	   a	  
paradoxical	  effect	  of	  TNFα	  blockers.	   	  
• Further	   randomized	   controlled	   clinical	   trials	   are	   necessary	   to	   investigate	   possible	   immune	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